Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Desidustat - Zydus Cadila

Next Previous
X
Search
Drug Profile

Desidustat - Zydus Cadila

Alternative Names: Oxemia; ZYAN-1; ZYAN-1-1001

Latest Information Update: 16 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zydus Cadila
  • Developer China Medical System; Zydus Cadila
  • Class Acetic acids; Amides; Antianaemics; Cyclopropanes; Quinolines; Small molecules
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia
  • Phase II COVID 2019 infections
  • Phase I Chemotherapy-induced anaemia

Most Recent Events

  • 14 Oct 2024 Zydus Cadila in collaboration with Indian Council of Medical Research plans a phase IIa proof-of-concept trial for Sickle cell anaemia (PO, Tablet)
  • 20 May 2022 Launched for Anaemia in India (PO)
  • 11 May 2022 Phase-I clinical trials in Chemotherapy-induced anaemia in USA (PO) (Zydus Cadila pipeline, May 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top